Analysis of Pharmacogenetic Information in Korea Drug Labels |
Lee, Mijin
(College of Pharmacy, Sunchon National University)
Kim, Sukyung (Graduate School of Clinical Biohealth, Ewha Womans University) Yee, Jeong (College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University) Gwak, Hye Sun (Graduate School of Clinical Biohealth, Ewha Womans University) Choi, Kyung Hee (College of Pharmacy, Sunchon National University) |
1 | Gnanasakthy A, Barrett A, Evans E, D'Alessio D, Romano CD. A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012-2016). Value Health 2019;22(2):203-9. DOI |
2 | Jung NH. A study on the improvement of pharmacogenomics guidance in Korea. M.S. Thesis for Pharmacy. Seoul National University. 2019. |
3 | National Institute of Food and Drug Safety Evaluation. Pharmacogenomic biomarker qualification guidelines. Available from http://www.nifds.go.kr/brd/m_15/view.do?seq=9116&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=28. Accessed August 12, 2020. |
4 | Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism 2015;64(3 Suppl 1):S16-21. DOI |
5 | Schuck RN, Grillo JA. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling. AAPS J 2016;18(3):573-7. DOI |
6 | Vivot A, Boutron I, Ravaud P, Porcher R. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. Genet Med 2015;17(9):733-8. DOI |
7 | Sadee W. Pharmacogenomics: Harbinger for the era of personalized medicine? Mol interv 2005;5(3):140-3. DOI |
8 | Hess GP, Fonseca E, Scott R, Fagerness J. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genet Res (Camb) 2015;97:e13. DOI |
9 | Whirl-Carrillo M, McDonagh EM, Hebert J, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92(4):414-7. DOI |
10 | Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Pharmacogenomics: prescribing precisely. Med Clin North Am 2019;103(6):977-90. DOI |
11 | Alvarado I, Wong M, Licinio J. Advances in the pharmacogenomics of adverse drug reactions. Pharmacogenomics J 2002;2(5):273. DOI |
12 | Silber BM. Pharmacogenomics, biomarkers, and the promise of personalized medicine, In: Kalow W, Meyer UA, Tyndale RF, eds. Pharmacogenomics. New York: Marcel Dekker Inc, 2001:11-32. |
13 | Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-5. DOI |
14 | Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001;286(18):2270-9. DOI |
15 | Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356(9242):1667-71. DOI |
16 | Choi JR, Kim J-O, Kang DR, et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet 2011;56(4):290-5. DOI |
17 | Ginsburg GS, Phillips KA. Precision medicine: From science to value. Health Aff (Millwood) 2018;37(5):694-701. DOI |
18 | Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. Warfarin pharmacogenomics in diverse populations. Pharmacotherapy 2017;37(9):1150-63. DOI |
19 | Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 Update. Clin Pharmacol Ther 2017;102(3):397-404. DOI |
20 | Shendre A, Dillon C, Limdi NA. Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics 2018;19(17):1357-71. DOI |
21 | Beutler E, Duparc S ; G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 2007;77(4):779-89. DOI |
22 | Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015;372(23):2229-34. DOI |
23 | Shin J, Johnson JA. Pharmacogenetics of β-Blockers. Pharmacotherapy 2007;27(6):874-87. DOI |
24 | Parry HM, Doney AS, Palmer CN, Lang CC. State of play of pharmacogenetics and personalized medicine in heart failure. Cardiovasc Ther 2013;31(6):315-22. DOI |
25 | Arranz MJ, Gonzalez-Rodriguez A, Perez-Blanco J, et al. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Transl Psychiatry 2019;9(1):177. DOI |
26 | Ministry of Food and Drug Safety. Pharmacogenomic information of Korean. Available from https://nedrug.mfds.go.kr/pbp/CCBBK03. Accessed June 23, 2020. |
27 | Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019;25(21):2539-48. DOI |
28 | Paez D, Tobena M, Fernandez-Plana J, et al. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br J Cancer 2019;120(2):190-5. DOI |
29 | Hiratsuka M, Sasaki T, Mizugaki M. Genetic testing for pharmacogenetics and its clinical application in drug therapy. Clin Chim Acta 2006;363(1-2):177-86. DOI |
30 | US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available from https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomicbiomarkers-drug-labeling. Accessed May 18, 2020. |
31 | Lee JH, Je MK, Cho MJ, Son HS. Trends in the use of big data in the health care field. The Journal of Korean Institute of Communications and Information Sciences 2014;32(1):63-75. |
32 | Kim Y-J, Jung S, Choi N, et al. Benzodiazepine prescription patterns for the elderly patients at ambulatory care in Korea. Korean Society for Pharmacoepidemiology and Risk Management 2008;1(1):60-7. |
33 | Ozawa S. Drug-drug interactions with consideration of pharmacogenetics. Yakugaku Zasshi 2018;138(3):365-71. DOI |
34 | Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286(5439):487-91. DOI |